SG11201912429RA - Personalized vaccine - Google Patents
Personalized vaccineInfo
- Publication number
- SG11201912429RA SG11201912429RA SG11201912429RA SG11201912429RA SG11201912429RA SG 11201912429R A SG11201912429R A SG 11201912429RA SG 11201912429R A SG11201912429R A SG 11201912429RA SG 11201912429R A SG11201912429R A SG 11201912429RA SG 11201912429R A SG11201912429R A SG 11201912429RA
- Authority
- SG
- Singapore
- Prior art keywords
- personalized vaccine
- personalized
- vaccine
- Prior art date
Links
- 229940038309 personalized vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305760 | 2017-06-21 | ||
| EP18305496 | 2018-04-23 | ||
| PCT/EP2018/066668 WO2018234506A2 (en) | 2017-06-21 | 2018-06-21 | PERSONALIZED VACCINE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201912429RA true SG11201912429RA (en) | 2020-01-30 |
Family
ID=62599637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201912429RA SG11201912429RA (en) | 2017-06-21 | 2018-06-21 | Personalized vaccine |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11969462B2 (ru) |
| EP (1) | EP3641803A2 (ru) |
| JP (2) | JP7334124B2 (ru) |
| KR (1) | KR20200026894A (ru) |
| CN (1) | CN111065406A (ru) |
| AU (1) | AU2018287159A1 (ru) |
| CA (1) | CA3067405A1 (ru) |
| IL (1) | IL271558B2 (ru) |
| SG (1) | SG11201912429RA (ru) |
| WO (1) | WO2018234506A2 (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3124905A1 (en) * | 2019-01-03 | 2020-07-09 | Jens KRINGELUM | Vaccines targeting neoepitopes |
| TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020176797A1 (en) * | 2019-02-27 | 2020-09-03 | Nektar Therapeutics | Immunotherapeutic combination for treating cancer |
| EP3842065A1 (en) | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| CN111303277A (zh) * | 2020-02-19 | 2020-06-19 | 中国人民解放军军事科学院军事医学研究院 | 一种抗天花病毒免疫球蛋白F(ab′)2及其制备方法 |
| WO2023209068A1 (en) | 2022-04-28 | 2023-11-02 | Carbocalyx Gmbh | Personalized anticancer vaccine comprising glycoengineered tumour cells or tumour cell fragments |
| WO2024062098A1 (en) | 2022-09-23 | 2024-03-28 | Transgene | Recombinant pseudocowpox virus encoding an interleukin-12 |
| CN116656730B (zh) * | 2023-05-25 | 2024-03-19 | 军事科学院军事医学研究院军事兽医研究所 | 一种表达狂犬病病毒g、m蛋白的重组金丝雀痘病毒及其构建方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US5672485A (en) | 1996-08-13 | 1997-09-30 | Regents Of The University Of Minnesota | Immortalized cell lines for virus growth |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| FR2790955B1 (fr) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| UA82466C2 (ru) | 2001-07-18 | 2008-04-25 | Бавариан Нордика А/С | Способ усиления амплификации хордопоксвируса |
| EP1418942B1 (en) | 2001-12-10 | 2005-08-03 | Bavarian Nordic A/S | Poxvirus-containing compositions and process for their preparation |
| WO2005007840A1 (en) | 2003-07-22 | 2005-01-27 | Vivalis | Production of poxviruses with adherent or non adherent avian cell lines |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| GB0502661D0 (en) | 2005-02-09 | 2005-03-16 | Stabilitech Ltd | A desiccated product |
| BRPI0618850A2 (pt) | 2005-11-21 | 2011-09-13 | Sanofi Pasteur Ltd | formulações de estabilização para vìrus recombinantes |
| JP5661243B2 (ja) | 2006-01-05 | 2015-01-28 | トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． | トリテロメラーゼ逆転写酵素 |
| HUE037866T2 (hu) * | 2006-06-20 | 2018-09-28 | Transgene Sa | Eljárás poxvírusok és poxvírus-készítmények elõállítására |
| PE20081723A1 (es) | 2007-01-30 | 2008-12-14 | Transgene Sa | Vacuna contra el papilomavirus |
| GB0705245D0 (en) | 2007-03-19 | 2007-04-25 | Stabilitech Ltd | Stable biological products |
| EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| US8012738B2 (en) | 2007-05-14 | 2011-09-06 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
| WO2008138649A2 (en) | 2007-05-15 | 2008-11-20 | Transgene S.A. | Signaling peptides |
| US8357531B2 (en) | 2007-07-03 | 2013-01-22 | Transgene S.A. | Immortalized avian cell lines |
| EP2176398B1 (en) | 2007-07-03 | 2016-12-28 | Transgene SA | Immortalized avian cell lines |
| BRPI0820578A2 (pt) | 2007-11-19 | 2015-06-16 | Transgène S A | Vírus da varíola, processo para preparar um vírus da varíola, composição, uso de um vírus da varíola ou de uma composição, e, método para tratar doenças |
| HUE028637T2 (en) | 2007-11-19 | 2016-12-28 | Transgene Sa | Oncolytic poxvirus vectors |
| EP2240573A4 (en) | 2008-02-12 | 2011-08-31 | Sanofi Pasteur Ltd | METHOD USING ION EXCHANGE AND GELFILTRATION CHROMATOGRAPHY FOR POXVIRUS CLEANING |
| EP2199400A1 (en) * | 2008-12-22 | 2010-06-23 | Emergent Product Development Germany GmbH | Single recombination system and methods of use |
| US8445270B2 (en) | 2009-05-12 | 2013-05-21 | Transgene S.A. | Immortalized avian cell lines and use thereof |
| KR102315754B1 (ko) * | 2010-05-14 | 2021-10-22 | 더 제너럴 하스피톨 코포레이션 | 종양 특이적 신생항원을 확인하는 조성물 및 방법 |
| RS64230B1 (sr) | 2011-05-24 | 2023-06-30 | BioNTech SE | Individualizovane vakcine protiv kancera |
| KR102022952B1 (ko) | 2011-08-05 | 2019-09-20 | 신라젠(주) | 백시니아 바이러스의 생산을 위한 방법 및 조성물 |
| AU2013289939B2 (en) * | 2012-07-12 | 2018-08-09 | Persimmune, Inc. | Personalized cancer vaccines and adoptive immune cell therapies |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| CN113337604A (zh) * | 2013-03-15 | 2021-09-03 | 莱兰斯坦福初级大学评议会 | 循环核酸肿瘤标志物的鉴别和用途 |
| KR20230145545A (ko) * | 2013-04-07 | 2023-10-17 | 더 브로드 인스티튜트, 인코퍼레이티드 | 개인맞춤화 신생물 백신을 위한 조성물 및 방법 |
| CA2932798C (en) * | 2013-12-06 | 2022-09-20 | The Broad Institute, Inc. | Formulations for neoplasia vaccines |
| CN106456747A (zh) | 2014-05-13 | 2017-02-22 | 巴法里安诺迪克有限公司 | 用表达肿瘤抗原的重组痘病毒和免疫检查点分子拮抗剂或激动剂治疗癌症的组合疗法 |
| EP3142689B1 (en) | 2014-05-13 | 2020-11-11 | Bavarian Nordic A/S | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3 |
| PE20180670A1 (es) | 2015-05-20 | 2018-04-19 | Broad Inst Inc | Neoantigenos compartidos |
| KR20180026670A (ko) | 2015-05-26 | 2018-03-13 | 어드박시스, 인크. | 맞춤형 전달 벡터-기반의 면역 요법 및 이의 용도 |
| TWI750122B (zh) * | 2015-06-09 | 2021-12-21 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
| CN108138099A (zh) | 2015-06-24 | 2018-06-08 | 阿德瓦希斯公司 | 用于个性化的基于递送载体的免疫疗法的制造装置和方法 |
| TWI765875B (zh) * | 2015-12-16 | 2022-06-01 | 美商磨石生物公司 | 新抗原辨識、製造及用途 |
| CA3056212A1 (en) * | 2016-04-07 | 2017-10-12 | Bostongene Corporation | Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines |
-
2018
- 2018-06-21 WO PCT/EP2018/066668 patent/WO2018234506A2/en unknown
- 2018-06-21 SG SG11201912429RA patent/SG11201912429RA/en unknown
- 2018-06-21 JP JP2019570982A patent/JP7334124B2/ja active Active
- 2018-06-21 CA CA3067405A patent/CA3067405A1/en active Pending
- 2018-06-21 EP EP18731146.9A patent/EP3641803A2/en active Pending
- 2018-06-21 IL IL271558A patent/IL271558B2/en unknown
- 2018-06-21 US US16/625,239 patent/US11969462B2/en active Active
- 2018-06-21 AU AU2018287159A patent/AU2018287159A1/en active Pending
- 2018-06-21 CN CN201880050941.2A patent/CN111065406A/zh active Pending
- 2018-06-21 KR KR1020207001211A patent/KR20200026894A/ko not_active Application Discontinuation
-
2023
- 2023-04-13 US US18/299,858 patent/US20230277639A1/en active Pending
- 2023-06-19 JP JP2023100296A patent/JP2023123609A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3067405A1 (en) | 2018-12-27 |
| WO2018234506A2 (en) | 2018-12-27 |
| JP7334124B2 (ja) | 2023-08-28 |
| CN111065406A (zh) | 2020-04-24 |
| JP2023123609A (ja) | 2023-09-05 |
| RU2020101489A (ru) | 2021-07-21 |
| JP2020530437A (ja) | 2020-10-22 |
| IL271558B2 (en) | 2024-01-01 |
| IL271558B1 (en) | 2023-09-01 |
| EP3641803A2 (en) | 2020-04-29 |
| US20230277639A1 (en) | 2023-09-07 |
| US20200138923A1 (en) | 2020-05-07 |
| IL271558A (en) | 2020-02-27 |
| RU2020101489A3 (ru) | 2021-10-21 |
| AU2018287159A1 (en) | 2020-01-16 |
| KR20200026894A (ko) | 2020-03-11 |
| US11969462B2 (en) | 2024-04-30 |
| WO2018234506A3 (en) | 2019-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201806688D0 (en) | No details | |
| GB201803663D0 (en) | No details | |
| GB201801258D0 (en) | No details | |
| GB201518684D0 (en) | Vaccine | |
| GB201721011D0 (en) | No details | |
| IL271558B1 (en) | A vaccine tailored to the individual | |
| GB201801628D0 (en) | No details | |
| GB201807647D0 (en) | No details | |
| GB201522132D0 (en) | Vaccine | |
| GB201710451D0 (en) | Comford aid | |
| GB201717719D0 (en) | No details | |
| GB201616904D0 (en) | Vaccine | |
| IL267264A (en) | Auxiliary substances | |
| GB201802344D0 (en) | No details | |
| GB201720890D0 (en) | No details | |
| GB201801239D0 (en) | No details | |
| GB201709043D0 (en) | No details | |
| GB201608821D0 (en) | Vaccines | |
| EP3568471A4 (en) | PERSONALIZED VACCINES | |
| GB201811382D0 (en) | Vaccine | |
| GB201621375D0 (en) | Adjuvants | |
| GB201618479D0 (en) | Adjuvants | |
| GB201712904D0 (en) | Vaccine | |
| GB201704126D0 (en) | Vaccine | |
| GB201703809D0 (en) | Vaccine |